15:59:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-21 Extra Bolagsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-09-28 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-12 Ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 Kvartalsrapport 2022-Q1
2022-05-11 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-23 Extra Bolagsstämma 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-12 Ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-08-11 Extra Bolagsstämma 2020
2020-05-15 Ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 Kvartalsrapport 2020-Q1
2020-05-14 Årsstämma 2020
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-08-16 Extra Bolagsstämma 2019
2019-05-17 Ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-23 Kvartalsrapport 2018-Q1
2018-02-26 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 Årsstämma 2017
2017-05-24 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Idag innehas verksamhet främst inom den nordiska marknaden. Bolaget grundades under 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.
2023-12-13 14:27:00

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces a new US sales structure that aims to further strengthen its presence with the CADScor System in the US market. The new structure includes three US regions, West & Southwest, Midwest & Northeast, and Southeast, each overseen by dedicated Regional Sales Leaders, all reporting directly to the CEO.

"The decision to implement a flat US organizational sales structure was made to streamline operations, to increase efficiency, to implement a unified approach to the US Sales process, with a focus on the right commercialization strategies and tactics, including sales training within the company," comments Fred Colen, Acting CEO of Acarix. "With this new structure, Acarix aims to enhance its customer support and sales efforts by having dedicated Regional Sales Leaders who will directly oversee sales representatives within their respective regions. This will allow for a more efficient and personalized approach to meeting customers' needs in different regions and further enhancing growth."

Acarix is pleased to announce the promotion of Erick Voorhees to the West & Southwest Regional Sales Leader and welcomes John Griffith as the new Regional Sales Leader for the Northeast and Midwest Region. John brings a decade of experience, including significant contributions to medical device companies such as Avail Medsystems, Inari Medical, Abbott, and 3M. Together, the Regional Sales Leaders bring a strategic approach and a deep understanding of the market, positioning them as valuable assets in advancing Acarix's growth and impact with the CADScor System in the United States.

Mike Buie has left the organization; we are grateful for his contributions.

One of the critical advantages of this new structure is the increased involvement of the Acarix CEO in the US Sales structure. The change highlights Acarix's commitment to sales growth as its top priority, providing exceptional customer support and ensuring its goals and values are reflected in all aspects of its commercial process. With the CEO's direct involvement, the Regional Sales Leaders will have the necessary support and guidance to drive sales and achieve success in their regions.

The enhanced regional focus facilitated by the new organizational structure will be complemented by maintaining consistency in national account coordination. Ownership of the Veterans Administration Hospitals will continue to reside under Erick Voorhees, while key National Integrated Delivery Network (IDN) relationships and business development opportunities will reside with the other Regional Leaders.

"I am confident that this new US Sales leadership structure will bring positive changes and strengthen our position with CADScor System in the US market. The company remains committed to providing physicians with innovative medical technology solutions and exceptional customer service. With the new Regional Sales Leaders in place and the direct involvement of the CEO, Acarix is well-positioned for growth and success in the US market", comments Fred Colen, Acting CEO of Acarix.